Cargando…

Strategies for Isolating and Propagating Circulating Tumor Cells in Men with Metastatic Prostate Cancer

Selecting a well-suited method for isolating/characterizing circulating tumor cells (CTCs) is challenging. Evaluating sensitive and specific markers for prostate cancer (PCa)-specific CTC identification and analysis is crucial. We used the CellCollector EpCAM-functionalized system (CC-EpCAM) and eva...

Descripción completa

Detalles Bibliográficos
Autores principales: Theil, Gerit, Bialek, Joanna, Weiß, Christine, Lindner, Felix, Fornara, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870963/
https://www.ncbi.nlm.nih.gov/pubmed/35204587
http://dx.doi.org/10.3390/diagnostics12020497
_version_ 1784656882828312576
author Theil, Gerit
Bialek, Joanna
Weiß, Christine
Lindner, Felix
Fornara, Paolo
author_facet Theil, Gerit
Bialek, Joanna
Weiß, Christine
Lindner, Felix
Fornara, Paolo
author_sort Theil, Gerit
collection PubMed
description Selecting a well-suited method for isolating/characterizing circulating tumor cells (CTCs) is challenging. Evaluating sensitive and specific markers for prostate cancer (PCa)-specific CTC identification and analysis is crucial. We used the CellCollector EpCAM-functionalized system (CC-EpCAM) and evaluated and developed a PCa-functionalized version (CC-PCa); we then compared CTC isolation techniques that exploit the physical and biological properties of CTCs. We established two cohorts of metastatic PCa patients (mPCa; 15 in cohort 1 and 10 in cohort 2). CTC cultivation experiments were conducted with two capturing methods (Ficoll and ScreenCell). The most sensitive detection rates and highest CTC counts were reached with the CC-PCa and ScreenCell system. Patients with ≥5 CTCs isolated with CC-EpCAM had an overall survival (OS) of 0.93 years, and patients with ≥5 CTCs isolated with CC-PCa had an OS of 1.5 years in cohort 1. Nevertheless, we observed the highest sensitivity and specificity for 24-month survival by the Ficoll with CD45 depletion and ScreenCell system with May-Grunwald Giemsa (MGG) staining. The EpCAM molecule is an essential factor related to OS for CTC isolation based on biological properties in mPCa patients. The best-suited CTC capture system is not limited to one characteristic of cells but adapted to downstream analysis.
format Online
Article
Text
id pubmed-8870963
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88709632022-02-25 Strategies for Isolating and Propagating Circulating Tumor Cells in Men with Metastatic Prostate Cancer Theil, Gerit Bialek, Joanna Weiß, Christine Lindner, Felix Fornara, Paolo Diagnostics (Basel) Article Selecting a well-suited method for isolating/characterizing circulating tumor cells (CTCs) is challenging. Evaluating sensitive and specific markers for prostate cancer (PCa)-specific CTC identification and analysis is crucial. We used the CellCollector EpCAM-functionalized system (CC-EpCAM) and evaluated and developed a PCa-functionalized version (CC-PCa); we then compared CTC isolation techniques that exploit the physical and biological properties of CTCs. We established two cohorts of metastatic PCa patients (mPCa; 15 in cohort 1 and 10 in cohort 2). CTC cultivation experiments were conducted with two capturing methods (Ficoll and ScreenCell). The most sensitive detection rates and highest CTC counts were reached with the CC-PCa and ScreenCell system. Patients with ≥5 CTCs isolated with CC-EpCAM had an overall survival (OS) of 0.93 years, and patients with ≥5 CTCs isolated with CC-PCa had an OS of 1.5 years in cohort 1. Nevertheless, we observed the highest sensitivity and specificity for 24-month survival by the Ficoll with CD45 depletion and ScreenCell system with May-Grunwald Giemsa (MGG) staining. The EpCAM molecule is an essential factor related to OS for CTC isolation based on biological properties in mPCa patients. The best-suited CTC capture system is not limited to one characteristic of cells but adapted to downstream analysis. MDPI 2022-02-15 /pmc/articles/PMC8870963/ /pubmed/35204587 http://dx.doi.org/10.3390/diagnostics12020497 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Theil, Gerit
Bialek, Joanna
Weiß, Christine
Lindner, Felix
Fornara, Paolo
Strategies for Isolating and Propagating Circulating Tumor Cells in Men with Metastatic Prostate Cancer
title Strategies for Isolating and Propagating Circulating Tumor Cells in Men with Metastatic Prostate Cancer
title_full Strategies for Isolating and Propagating Circulating Tumor Cells in Men with Metastatic Prostate Cancer
title_fullStr Strategies for Isolating and Propagating Circulating Tumor Cells in Men with Metastatic Prostate Cancer
title_full_unstemmed Strategies for Isolating and Propagating Circulating Tumor Cells in Men with Metastatic Prostate Cancer
title_short Strategies for Isolating and Propagating Circulating Tumor Cells in Men with Metastatic Prostate Cancer
title_sort strategies for isolating and propagating circulating tumor cells in men with metastatic prostate cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870963/
https://www.ncbi.nlm.nih.gov/pubmed/35204587
http://dx.doi.org/10.3390/diagnostics12020497
work_keys_str_mv AT theilgerit strategiesforisolatingandpropagatingcirculatingtumorcellsinmenwithmetastaticprostatecancer
AT bialekjoanna strategiesforisolatingandpropagatingcirculatingtumorcellsinmenwithmetastaticprostatecancer
AT weißchristine strategiesforisolatingandpropagatingcirculatingtumorcellsinmenwithmetastaticprostatecancer
AT lindnerfelix strategiesforisolatingandpropagatingcirculatingtumorcellsinmenwithmetastaticprostatecancer
AT fornarapaolo strategiesforisolatingandpropagatingcirculatingtumorcellsinmenwithmetastaticprostatecancer